Medication delivery control and pulse wave detection apparatus

• US 5,730,137 A
• Filed: 11/22/1994
• Issued: 03/24/1998
• Est. Priority Date: 11/30/1993
• Status: Expired due to Term

• Current Assignee: Seiko Epson Corporation (Seiko Group)
• Original Assignee: Seiko Epson Corporation (Seiko Group)
• Inventors: Amano, Kazuhiko, Kodama, Kazuo, Ishiyama, Hitoshi
• Primary Examiner(s): Nasser, Robert L.
• Application Number:
  US08/343,301
• Time in Patent Office: 1,218 Days
• Field of Search: 128/672, 128/677, 128/680-3, 128/687, 128/690, 604/50, 604/65-67
• US Class Current: 600/485
• CPC Class Codes: A61B 2562/02 Details of sensors specially adapted for in-vivo measurements
• CPC Class Codes: A61B 5/02007 Evaluating blood vessel condition, e.g. elasticity, compliance
• CPC Class Codes: A61B 5/021 Measuring pressure in heart or blood vessels A61B5/0205 takes precedence
• CPC Class Codes: A61B 5/02108 from analysis of pulse wave characteristics
• CPC Class Codes: A61B 5/4839 combined with drug delivery
• CPC Class Codes: A61B 5/7239 using differentiation including higher order derivatives

Abstract

A microcomputer performs a frequency analysis of pulse waves which are taken at regular time intervals from a patient through a pulse wave detection section. Then, if the amplitudes and phases of the spectra of the pulse waves fulfill some set conditions, either α-blocker or β-blocker is given to the patient, and the patient'"'"'s circulatory activity is maintained in a stable condition.

Claims

1. A medication delivery control apparatus, comprising:

pulse wave detection means for obtaining pulse waves from a patient at predetermined regular time intervals;

pulse wave analysis means for determining waveform parameters of the pulse waves; and

medication delivery control means for causing delivery of medication if the waveform parameters meet preset conditions.

2. The medication delivery control apparatus of claim 1, further comprising means for measuring the blood pressure of the patient;

and wherein said medication delivery control means causes the delivery of medication if the waveform parameters meet the preset conditions and the blood pressure is greater than a preset value.

3. The medication delivery control apparatus of claim 1, wherein said pulse wave analysis means includes means for determining the spectra of the pulse waves by applying a frequency analysis to the pulse waves and means for calculating the waveform parameters based on the spectra.

4. The medication delivery control apparatus of claim 3, wherein the waveform parameters are composed of amplitude ratios between respective harmonic spectra and fundamental spectra of the pulse waves.

5. The medication delivery control apparatus of claim 3, wherein the waveform parameters are composed of phase differences between respective harmonic spectra and fundamental spectra of the pulse waves.

6. The medication delivery control apparatus of claim 3, wherein the waveform parameters are composed of distortion of the pulse waves calculated from the spectra of the pulse wave.

7. A pulse wave detection apparatus, comprising:

pulse wave detection means for detecting pulse waves from a patient; and

pulse wave analysis means for determining waveform parameters of the pulse waves, and

wherein said pulse wave analysis means includes means for determining the spectra of the pulse waves by applying a frequency analysis to the pulse waves and means for calculating the waveform parameters based on the spectra.

8. The pulse wave detection apparatus of claim 7, wherein the waveform parameters are composed of amplitude ratios between respective harmonic spectra and fundamental spectra of the pulse waves.

9. The pulse wave detection apparatus of claim 7, wherein the waveform parameters are composed of phase differences between respective harmonic spectra and fundamental spectra of the pulse waves.